Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation - Clinical Trial NCTNCT06744647

Business Opportunities for NCT06744647

Connect with principal investigators, study coordinators, and key decision makers for this PHASE2 trial studying investigational therapy for Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR.

Clinical Trial Information

Study Sponsor

Sponsor information available

Drug/Intervention

Study intervention details available

Therapeutic Area

Therapeutic area information available

Study Phase

PHASE2

Study Status

ACTIVE_NOT_RECRUITING

NCT Number

NCTNCT06744647

Find Contact Information

Access exclusive contact details for:

• Principal investigators and sub-investigators
• Study coordinators and research staff
• Site directors and facility contacts
• Sponsor representatives and CRO partners
• Business development professionals
• Clinical operations managers

Clinical Trial Locations

This study has 49 locations across United States, Brazil, Canada, China, Korea, Republic of, Spain, Taiwan, United Kingdom.

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

• Discover clinical trials before competitors
• Access exclusive contact information
• Track sponsor pipelines and opportunities
• Connect with decision makers directly
• Win more business partnerships